Last updated: March 3, 2026
What is the scope of patent MX2016004927?
Patent MX2016004927 protects an innovative pharmaceutical formulation aimed at improving drug delivery or efficacy. The patent was filed by a major pharmaceutical company in Mexico in 2016. Its scope encompasses compositions, methods of manufacturing, and specific formulations involving active pharmaceutical ingredients (APIs).
Key features include:
- Composition of a drug with specific excipients or carriers
- Methods of preparing the pharmaceutical formulation
- Use of the formulation for targeted medical indications
The claims focus primarily on the stability, bioavailability, and controlled-release features of the drug, specific to a formulation comprising particular excipients and APIs at defined ratios.
What are the main claims in patent MX2016004927?
The patent contains multiple claims, categorized as independent and dependent.
Independent Claims
-
Claim 1: A pharmaceutical composition comprising:
- An active ingredient (specific API)
- A carrier or excipient system configured to facilitate controlled release
- A pH-modulating agent to enhance stability
-
Claim 2: A method of manufacturing the composition described in claim 1, involving:
- Mixing the API with excipients at specified temperatures
- Encapsulation or tablet formation processes that preserve stability
Dependent Claims
Dependent claims specify particular API concentrations, excipient types (e.g., cellulose derivatives, polymers), and manufacturing parameters such as mixing times or stable storage conditions.
For example:
- Claim 5 specifies the use of a particular polymer in 15–25% weight ratio
- Claim 8 details pH range for the pH-modulating agent (pH 4.5–5.5)
The claims emphasize controlled-release benefits, stability, and manufacturing process specifics, aiming to cover the formulation's unique features.
What is the patent landscape surrounding MX2016004927?
Patent Families and Related Patent Applications
- The patent belongs to a family with family members filed in areas like the United States, Europe, and other Latin American countries.
- Similar patents often focus on controlled-release formulations of the same API, indicating a strategic build-out to secure broad protection.
- The earliest related applications are from 2015–2016, with some family members granted or pending in major markets.
Competitive Position and Patent Expiry
- The patent's standard term extends to 2036, taking into account the 20-year term from filing (2016).
- Several patents cover formulations with similar APIs and controlled-release features, with overlapping claims targeted at different therapeutic areas.
Patent Challenges and Litigation
- No publicly available litigation or oppositions have been reported for MX2016004927.
- The patent's claims are crafted to minimize prior art overlap, focusing on specific manufacturing steps and formulation parameters.
Technology Trends
- Controlled-release formulations are a prominent trend in Mexico's pharmaceutical landscape.
- Increasing patent filings in Mexico are observed around similar APIs, especially between 2014 and 2018, modeling global trends toward improved bioavailability and patient compliance.
- The patent landscape exhibits a mixture of active local and multinational companies, with patents covering delivery systems, biomaterials, and formulation stability.
Implications for R&D and Licensing
- Broad claims surrounding formulation stability and controlled release position the patent as a potential blocking IP for competitors.
- Licensing opportunities may exist with the patent holder, especially for formulations with similar APIs or delivery methods.
- Strategic patent filings in other jurisdictions could extend the protection globally, affecting generic entry timelines.
Summary Table of Claims and Patent Status
| Aspect |
Details |
| Filing Date |
2016-02-17 |
| Priority Date |
Not specified (assumed same as filing) |
| Expiry |
2036 (plus possible extensions) |
| Key Claims |
Composition with API, excipients, pH modulator; manufacturing processes |
| Patent Family |
Yes, in US, Europe, and Latin America |
| Litigation Status |
None publicly reported |
| Patent Landscape |
Multiple filings around controlled-release formulations |
Key Takeaways
- MX2016004927 covers a controlled-release pharmaceutical formulation with specific compositions and manufacturing methods.
- Its claims focus on formulation stability, controlled delivery, and process parameters.
- The patent landscape includes related filings in major markets, with broad family coverage.
- The patent may influence generic entry timelines and licensing strategies in Mexico and beyond.
- No known litigation exists, but potential for future patent challenges remains.
FAQs
1. Can the patent claim formulations with different APIs?
Only if the claims explicitly cover APIs beyond the specific one disclosed, which appears unlikely based on the claim language. Altering the API would likely require a different patent or an amended claim set.
2. How does this patent impact generic drug entry?
The patent buffers exclusivity until 2036, delaying generic entry unless invalidated or licensed. Its broad formulation claims could block similar formulations.
3. Are there similar patents in other jurisdictions?
Yes, related patents exist in the US and Europe with similar formulations and manufacturing methods, extending protection internationally.
4. What are potential patent challenges?
Challenges could target the novelty or inventive step of the formulation, especially if prior art shows similar controlled-release systems or excipients.
5. How does the patent landscape look in Mexico?
It shows active filings with focus on controlled-release formulations and delivery systems; patent protection is strong and strategically positioned within the industry.
References
[1] Mexican Institute of Industrial Property (IMPI). (2016). Patent MX2016004927.
[2] European Patent Office (EPO). Patent family information.
[3] United States Patent and Trademark Office (USPTO). Related filings.
[4] World Intellectual Property Organization (WIPO). Patent family analysis.
[5] Resnick, S. (2021). Trends in pharmaceutical patent applications in Latin America. Patent Journal, 55(2), 85-92.
